Reinforces the value of GLP-1 RAs in slowing CKD progression Demonstrates the power of real-world data and external control arms Supports broader access, reimbursement, and clinical adoption Read more: #RealWorldEvidence #Semaglutide #T2DM #CKD #Pharma #HealthOutcomes #GLP1 #RCT #ExternalControlArm To view or add a comment, sign in More Relevant Posts Lillys Oral GLP-1 Orforglipron Delivers Strong Phase 3 Results Lillys oral GLP-1, orforglipron, showed superior glycemic control in two Phase 3 trials, reinforcing its potential as a foundational therapy for T2D: - ACHIEVE-2 (vs
She said dropping coverage for obesity patients feels like weight-based discrimination because other chronic diseases qualify
In the last year, a little known drug originally prescribed to people with type 2 diabetes has shot into the headlines
The injection is typically given once weekly on the same day each week
Immunosenescence, characterized by dysregulation of signaling pathways and altered senescence/regulatory capacity across immune cell populations, may predispose individuals to diverse age-associated pathologies
Weeks 9 through 16: therapeutic dosing Moving to 1.0mg and eventually 1.7mg per week represents the therapeutic range where semaglutide produces its most significant effects
